Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedigusMDGSW 12 Debt-to-Equity is 0.38 as of Dec. 2024, which is 153% above its 10-year median of 0.15. GuruFocus rates MDGSW with a GF Score™ of 12/100. The stock has 6 warning signs investors should review.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Medigus's Debt-to-Equity or its related term are showing as below:
MDGSW'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.15 Max: 0.42
Current: 0.38
During the past 13 years, the highest Debt-to-Equity Ratio of Medigus was 0.42. The lowest was 0.01. And the median was 0.15.
MDGSW's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.24
vs MDGSW: 0.38
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Medigus Debt-to-Equity Related Terms
Medigus Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Medigus's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDGSW vs RMSL, HSDT, ALRTF: Debt-to-Equity Comparison
For the Medical Devices subindustry, Medigus's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigus Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medigus's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Medigus's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigus (MDGSW) has a Debt-to-Equity of 0.38 as of Dec. 2024. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Medigus and its competitors. This is 153% above median its historical median of 0.15. Over the past decade, Medigus' Debt-to-Equity has ranged from 0.01 to 0.42.
Is Medigus' Debt-to-Equity too high?
Medigus' current Debt-to-Equity of 0.38 is 153% above median its 10-year median of 0.15. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.42. The Medical Devices & Instruments industry median Debt-to-Equity is 0.24. Medigus' value of 0.38 is 58.3% above this industry median. Overall, Medigus has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Medigus' Debt-to-Equity compare to RMSL and HSDT?
Medigus' Debt-to-Equity of 0.38 can be compared against companies in the Medical Devices & Instruments industry. The industry median Debt-to-Equity is 0.24. Medigus' value of 0.38 is 58.3% above this benchmark. Historically, Medigus' own Debt-to-Equity has ranged from 0.01 to 0.42 over the past decade. While the company's 10-year median is 0.15 vs. the industry median of 0.24, Medigus has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 697 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medigus's current Debt-to-Equity of 0.38 is 58.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Medigus and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medigus's current Debt-to-Equity is 0.38, which is 153% above median its own 10-year median of 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigus stock overvalued right now?
Medigus (MDGSW) has a current Debt-to-Equity of 0.38. The current Debt-to-Equity is 0.38, which is 153% above median its 10-year median of 0.15 and 58.3% above the Medical Devices & Instruments industry median of 0.24. Medigus' overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Medigus (MDGSW), the current Debt-to-Equity is 0.38 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xylo Technologies Ltd is an Israel-based medical device company. The company is engaged in the development, manufacturing, and marketing of direct vision systems for minimally invasive medical procedures and safety systems for drones and the electric vehicle (EV) sector. The key product of the company is the MUSE (Medigus Ultrasonic Surgical Endostapler) system is a single-use device for the incision-less treatment of GERD (gastroesophageal reflux disease), which is based on proprietary platform technology and know-how. The company operates in four segments are: Corporate, Online advertising & internet traffic routing, Online event management, real-estate and electronics. The company's geographical segments include USA, Europe, Great Britain, Israel, Canada, Asia and others.
12GF Score
Get the complete analysis for MDGSW
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDGSW has been successfully added to your 
